GLP-3 R (Retatrutide)
Triple Receptor Agonist — Next-Level Weight Loss
Retatrutide (GLP-3 R) is a triple GLP-1/GIP/glucagon receptor agonist showing 24% body weight reduction in Phase II — the most potent weight loss peptide in clinical development.
- 24.2% body weight reduction in Phase II trial at 48 weeks — unprecedented
- Triple GLP-1/GIP/glucagon receptor agonism — three simultaneous weight loss mechanisms
- Glucagon agonism raises basal metabolic rate — burns more calories at rest
- Significant reduction in liver fat (NASH-relevant)
- Reduces triglycerides and blood pressure in addition to weight
COA verified · US domestic shipping
Retatrutide (GLP-3 R): The Triple Receptor Agonist Rewriting Weight Loss Science
24% Weight Reduction
Phase II results: 24.2% body weight reduction at 48 weeks — with no plateau. The highest weight loss ever demonstrated in a clinical trial at that point.
Triple Mechanism
GLP-1 + GIP + glucagon receptor activation — the glucagon component raises basal metabolic rate and drives liver fat oxidation beyond what dual agonists achieve.
Liver Fat Reduction
Significant hepatic fat reduction — making retatrutide potentially the first anti-obesity agent with strong NASH (liver disease) efficacy simultaneously.
No Plateau
Unlike semaglutide, retatrutide showed continued weight loss trajectory at 48 weeks with no plateau — suggesting even greater efficacy over longer treatment.
The Science Behind GLP-3 R (Retatrutide)
Retatrutide is a triple receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors — representing the next frontier beyond dual agonists like tirzepatide. It is in late-stage clinical development and has already demonstrated the most impressive weight loss data in clinical trial history.
▸Triple Mechanism
Adding glucagon receptor agonism to the GIP+GLP-1 mechanism introduces a third metabolic pathway:
▸Glucagon receptor:
→Directly stimulates hepatic fat burning (liver fat oxidation)
→Increases basal energy expenditure (raises metabolic rate)
→Promotes lipolysis in adipose tissue
→Reduces hepatic fat accumulation
This addition explains why retatrutide outperforms tirzepatide in weight loss efficacy.
▸Phase II Trial Results
In the Phase II trial (N Engl J Med, 2023):
→24.2% body weight reduction at 48 weeks (highest dose)
→Continued weight loss trend at week 48 with no plateau in sight
→Superior to tirzepatide data at comparable timepoints
→Significant reductions in liver fat, triglycerides, and blood pressure
▸Where It Stands
Retatrutide is currently in Phase III trials. If results hold, it will represent the most effective obesity therapy ever developed by a substantial margin.
Complete GLP-3 R (Retatrutide) Benefits
- 24.2% body weight reduction in Phase II trial at 48 weeks — unprecedented
- Triple GLP-1/GIP/glucagon receptor agonism — three simultaneous weight loss mechanisms
- Glucagon agonism raises basal metabolic rate — burns more calories at rest
- Significant reduction in liver fat (NASH-relevant)
- Reduces triglycerides and blood pressure in addition to weight
- No weight loss plateau observed at 48 weeks — continued trajectory
- Most advanced compound in pipeline for obesity treatment
- Phase III trials underway with high probability of approval
GLP-3 R (Retatrutide) Dosing Protocol
Phase II Escalation Protocol (Reference):
• 2mg weekly × 4 weeks
• 4mg weekly × 4 weeks
• 8mg weekly × 4 weeks
• 12mg weekly (maintenance)
Injection: Once weekly subcutaneous.
Note: Phase III compound. Clinical data pending.
All information on this site is for educational purposes only. Always consult with a qualified healthcare provider before use. COA documentation is available from Apollo Peptide Sciences for all products.
Get GLP-3 R (Retatrutide)
Apollo Peptide Sciences — COA verified, US domestic, fast shipping.
Shop View Stack ProtocolsGLP receptor agonists work via hypothalamic appetite regulation and metabolic enhancement — proven in large-scale clinical trials.
All Weight Loss PeptidesStacks Best With
Stack GLP-3 R (Retatrutide) With
Anti-AgingNAD+ 500mg
Cellular Energy & Longevity Cofactor
NAD+ is the master cellular energy molecule that declines 50% by age 50 — supplementation restores sirtuin activity, DNA repair, and mitochondrial function.
Weight LossGLP-1 S (Semaglutide)
Next-Gen GLP-1 Receptor Agonist for Weight Loss
Semaglutide (GLP-1 S) is a GLP-1 receptor agonist with clinical trials showing 15-20% body weight reduction — the most effective pharmacological weight loss agent studied.
Weight LossGLP-2 T (Tirzepatide)
Dual GIP/GLP-1 Agonist — Superior Weight Loss
Tirzepatide (GLP-2 T) is a dual GIP/GLP-1 receptor agonist showing up to 22.5% body weight reduction in trials — outperforming semaglutide in head-to-head data.